A practical reference on Drug affinity complex: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
== Genomes == The availability of genomes of many organisms on the tree of life has opened up the possibility to study how the adhesome evolved from the unicellular relatives of animals through simple animals (e.g. sponges) to mammals. Surprisingly, the majority of cadherin adhesome proteins existed long before multicellularity and had other functions in cells. Later, with the emergence of the cadherin-catenin-actin structure they were co-opted into the cadhesome.
== Sequels == Half-Life 2 was followed by the episodic sequels Episode One (2006) and Episode Two (2007). After canceling Episode Three and several further Half-Life projects, Valve released a prequel, Half-Life: Alyx, in 2020.
Actinides seem to be a little less hard than lanthanides, probably due to a longer spatial extent of 5f atomic orbitals with respect to 4f ones, then a selective separation is possible thanks to ligands bearing soft donors such as nitrogen and sulfur atoms, by a different bonding nature compared to hard donors. Despite the potential separation of actinides, a direct extraction from the PUREX raffinate is very hard, due to the presence of many other interfering species in the feed such as activation and fission products. In this perspective, advanced separation processes involving very selective extracting agents are required to achieve an efficient partitioning for the following transmutation process. To sum up, knowledge of hydration, acid-base interactions, kinetics and thermodynamic stabilities and speciation of actinide and lanthanide ions with ligands is of great value to understand a solvent extraction process and to design new and promising extracting agents.
Sources: en.wikipedia.org
In the Vulgate Cycle, and the Prose Tristan, Pellinore is called the Maimed King after being wounded by a holy spear, having doubted the powers of the Grail. Uniquely in the Livre d'Artus version of the Vulgate Merlin Continuation, there are also two cousins by the name Pellinore, both being the Maimed Kings destined to be healed by Galahad on the same day: one being a former king of Wales, now living in the Castle of Marvels, and the other one being the lord of Listenois (Wasteland) and Corbenic.
Labour Party leader Sir Keir Starmer publishes details of his tax returns, a day after the prime minister. The Westminster Parliament announces that the TikTok app will be banned on "all parliamentary devices and the wider parliamentary network". The British Medical Association announces that junior doctors in England will stage a four-day strike from 11 to 15 April in their continued quest for a 35% pay rise. England footballer Harry Kane becomes the England national football team all-time leading goalscorer with 54 goals in a 2–1 win vs Italy national football team, surpassing the previous record of 53 goals held by Wayne Rooney, who broke the record back in September 2015. 24 March Charles III's state visit to France, his first official overseas visit as King, is postponed following a request by French president Emmanuel Macron after unions threatened to stage a day of protests over pension reforms during his visit. MPs vote to back the Protection from Sex-based Harassment in Public Bill, which will make catcalling, following someone or blocking their path an offence in England and Wales with a punishment of up to two years in prison. COVID-19 in the UK: The final Coronavirus Infections Survey is published by the Office for National Statistics, with data for the week up to 13 March. It shows an increase in COVID-19 cases for England, but an uncertain picture for the rest of the UK.
=== N- and C-termini === The peptides matched during protein identification do not necessarily include the N- or C-termini predicted for the matched protein. This may result from the N- or C-terminal peptides being difficult to identify by MS (e.g. being either too short or too long), being post-translationally modified (e.g. N-terminal acetylation) or genuinely differing from the prediction. Post-translational modifications or truncated termini may be identified by closer examination of the data (i.e. de novo sequencing). A repeat digest using a protease of different specificity may also be useful.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.